Q-omics provides the consensus-scored MRPL16 profile across patient tissues and cancer cell-line models. MRPL16 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MRPL16 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, MRPL16 protein abundance shows 21,529 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, LIHC, and LSCC as cancer lineages where MRPL16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL16 survival associations across molecular data types. MRPL16 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL16 RNA expression–survival associations across cancer types. High MRPL16 expression shows unfavorable associations in LUAD, UVM, KICH, HNSC and CESC, but favorable associations in BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MRPL16 RNA expression.
This table summarizes MRPL16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL16 shows lower tumor expression in THCA and higher tumor expression in LIHC, COAD, BLCA, HNSC and UCEC. The LIHC box plot shows higher MRPL16 RNA expression in tumor versus normal tissue (log2 FC = +0.514, t-test p < 0.001).
This table shows molecular features associated with MRPL16 in patient tissues and cancer cell lines. In patient samples, MRPL16 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
